BioNTech Results Presentation Deck

Broad progress in executing our multi-platform 10 strategy 7 mRNA Cancer Vaccines Randomized Phase 2 trial starts for FixVac and iNeST in multiple solid tumors expected in 2H 2020 Cell Therapies Phase 1/2 trial start for CARVac planned in 2H 2020 Filed IND for Phase 1 trial of ex- vivo neoantigen T cell therapy ff1 sti argeting Cancer Antibodies Immunomodulai + Small Molecule Immunomodulators Next Generation Immunomodulators First Phase 1/2 data expected for PD- L1 x 4-1BB antibody in 2H 2020 Engineered Cytokines First Phase 1/2 data from intratumoral mRNA in 2H 2020 Ribocytokines to enter the clinic in 2021 Ongoing Phase 1/2 trial for CA 19-9 antibody in pancreatic cancer First-in-human Phase 1/2 trial for TLR7 agonist initiated in early July 2020 Potential for multiple blockbuster opportunities with powerful combinations BIONTECH

View entire presentation